Zantac’s manufacturers were on a roll. Their defense had exacted a spate of favorable decisions and jury verdicts. Yet, on October 9, Glaxo Smith Kline (GSK) suddenly settled 93% of the remaining cases – for 2.2 billion dollars.
Valisure whistleblower
ACSH relies on donors like you. If you enjoy our work, please contribute.
Make your tax-deductible gift today!
Popular articles
ACSH Podcasts
